[189 Pages Report] The In-Vitro Diagnostics Quality Control Market size was estimated at USD 1.37 billion in 2023 and expected to reach USD 1.48 billion in 2024, at a CAGR 8.34% to reach USD 2.41 billion by 2030.
In-vitro diagnostics quality control is primarily utilized to ensure the accuracy and precision of diagnostic tests by observing and assessing the performance and functioning of medical instruments, equipment, processes, reagents, and personnel involved in the testing procedure. This quality control process involves various activities to assess the validity of results produced by in-vitro diagnostic tests. The growing incidence of non-communicable diseases and infectious diseases has expanded the need for high-quality in-vitro diagnostics testing methods. Third-party quality controls are in high demand due to the various services offered. Government regulations to ensure the safety of diagnostics devices and services are among the main factors increasing the use of in-vitro diagnostic quality control components. The high cost of IVD quality control services and the concerns associated with the inaccuracy of the testing methods impede their adoption in clinical laboratories and hospitals. Market players are conducting R&D activities to introduce efficient and smart quality control methods to sustain their utilization in healthcare & life sciences applications.
The Americas is home to several large multinational companies that produce in-vitro diagnostic quality control instruments and accessories, with strong product lines distinguished by reliable performance and competitive pricing. Strict government regulations to maintain the quality of diagnostics products, powered by the U.S. FDA, Health Canada, and other regulatory authorities, have been elevating the need for effective in-vitro quality control methods in the Americas. Asia has various suppliers offering different in-vitro diagnostic quality control products at varying prices. Global players in Europe are conducting R&D activities to offer more comprehensive solutions, including multiple platforms and formats such as instrumentation, software, and consumables for quality control. With the growing prevalence of diseases and the need for in-vitro diagnostics across the Americas, Europe, and Asia, market players have been constantly working on acquiring approvals for their products from the respective regulatory bodies in the region.
The market dynamics represent an ever-changing landscape of the In-Vitro Diagnostics Quality Control Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
- Market Drivers
- Prevalence of chronic and infectious diseases and need for in-vitro diagnostics
- Growing demand for point-of-care diagnostic technologies and third-party quality controls
- Government regulations to ensure the safety of diagnostics devices and services
- Market Restraints
- High cost of IVD quality control services
- Market Opportunities
- R&D activities to introduce smart quality control for in-vitro diagnostics
- Technological advancement in silicon technology and multianalyte controls
- Market Challenges
- Stringent regulations for approval of IVD test products and inaccuracy issues
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the In-Vitro Diagnostics Quality Control Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the In-Vitro Diagnostics Quality Control Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the In-Vitro Diagnostics Quality Control Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the In-Vitro Diagnostics Quality Control Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the In-Vitro Diagnostics Quality Control Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the In-Vitro Diagnostics Quality Control Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the In-Vitro Diagnostics Quality Control Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the In-Vitro Diagnostics Quality Control Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the In-Vitro Diagnostics Quality Control Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the In-Vitro Diagnostics Quality Control Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the In-Vitro Diagnostics Quality Control Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the In-Vitro Diagnostics Quality Control Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Indian Subsidiary Acquires ISO13485 Certification
The in-vitro diagnostics quality control market remains highly competitive, with companies striving to provide their customers with innovative solutions. Takara Bio Inc., a world leader in this space, recently launched its new Takara SYBR Premix Ex Taq II (Perfect Real Time) qPCR Kit. This kit provides users with enhanced performance and longer shelf life, thus enabling a more comprehensive range of applications and more reliable results. In addition, its improved sensitivity allows measurements that were once difficult or impossible to perform. With this next-generation qPCR Kit, Takara Bio further cements its place as the global leader in delivering effective and reliable in-vitro diagnostics solutions. [Published On: 2023-04-19]
Werfen Completes Acquisition of Immucor
As part of its strategy to expand in the in-vitro diagnostics quality control market, Werfen recently acquired Immucor. This acquisition increases Werfen's portfolio in immunohematology and infectious disease products and strengthens its position as a leading global healthcare solutions provider. Immucor's presence in over 100 countries gives Werfen access to an international network of customers while also providing them with a comprehensive range of technologies, products, services, and support. Combining both companies will enable a better understanding and monitoring of patient health outcomes, which could lead to improved diagnostics that offer more accuracy and reliability for clinicians. This is a significant step ahead for the in-vitro diagnostics quality control market and will bring substantial growth opportunities. [Published On: 2023-03-16]
EDX Completes Acquisition of IVD Products Developer Torax Biosciences
EDx's acquisition of Torax Biosciences is an exciting development to help equip laboratories with the necessary tools to deliver accurate results quickly and efficiently. This is especially beneficial for infectious disease testing, where speed and accuracy are essential for patient care. This move by EDx also increases its global presence and ability to respond quickly to customer needs across all time zones. Overall, this acquisition is essential in improving the quality of in vitro diagnostics globally. [Published On: 2023-02-20]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the In-Vitro Diagnostics Quality Control Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the In-Vitro Diagnostics Quality Control Market, highlighting leading vendors and their innovative profiles. These include Ortho-Clinical Diagnostics, Inc., CalibreScientific Global Distribution, Inc., Qiagen N.V., Microbix Biosystems Inc., Becton, Dickinson and Company, Abbott Laboratories, Sun Diagnostics, LLC, Devyser AB, Fortress Diagnostics, Micro Bio Logics, Inc., Danaher Corporation, Hologic, Inc., Grifols, S.A., Agilent Technologies, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Randox Laboratories Ltd., ZeptoMetrix Corporation, LGC Limited, Streck, Inc., Quidel Corporation, F. Hoffmann-La Roche Ltd., Seegene Inc., DiaSorin S.p.A., Maine Molecular Quality Controls, Inc., Bio-Techne Corporation, bioMerieux Inc., Sysmex Corporation, and Siemens AG.
This research report categorizes the In-Vitro Diagnostics Quality Control Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Offering
- Data Management Solutions
- Quality Assurance Services
- Quality Control Products
- Serum/Plasma-Based Controls
- Urine-Based Controls
- Whole-Blood-Based Controls
- Distributor
- OEM
- Third-Party Control Manufacturers
- Independent Manufacturer Controls
- Instrument-Specific Controls
- Application
- Clinical Chemistry
- Coagulation or Hemostasis
- Hematology
- Immunochemistry
- Microbiology
- Molecular Diagnostics
- End-User
- Clinical Laboratories
- Hospitals
- Research & Academic Institutes
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- In-Vitro Diagnostics Quality Control Market, by Offering
- In-Vitro Diagnostics Quality Control Market, by Distributor
- In-Vitro Diagnostics Quality Control Market, by Application
- In-Vitro Diagnostics Quality Control Market, by End-User
- Americas In-Vitro Diagnostics Quality Control Market
- Asia-Pacific In-Vitro Diagnostics Quality Control Market
- Europe, Middle East & Africa In-Vitro Diagnostics Quality Control Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 24]
- List of Tables [Total: 558]
- List of Companies Mentioned [Total: 30]
Quality control measures must be in place to ensure the accuracy and reliability of in-vitro diagnostic tests. These measures should ensure that the test system performs within predetermined specifications and that any variation is detected and resolved. Quality control involves several steps, from specimen collection, handling, processing, and analysis. It requires using quality control materials or samples that mimic the patient specimen's characteristics and permit the assessment of laboratory performance.
Traditional quality control measures involve analyzing quality control materials alongside patient specimens to ensure the accuracy of results. However, this approach may not detect errors due to the system's stability or user errors. To address these limitations, smart quality control measures are being introduced. These measures involve using software and hardware to monitor performance continuously. The system generates alerts when performance characteristics deviate from predefined limits, enabling rapid response and instrument maintenance.
Smart quality control measures have several benefits, critical of which is increased efficiency. The continuous analysis and system performance monitoring reduces the need for manual testing at preset intervals and expedites issue resolution. Additionally, smart measures can provide real-time analysis of daily performance trends, enabling proactive decision-making for instrument maintenance and diagnostic performance.
In-vitro diagnostic quality control measures are also evolving in response to advances in testing technology. Point-of-care testing has gained popularity across different healthcare settings as it allows rapid, on-site diagnosis and treatment delivery. Introducing smart quality control measures for point-of-care testing will enable clinicians to receive real-time quality assurance results, which is critical in guiding treatment decisions.
In-vitro diagnostic quality control measures are important for ensuring the accuracy and reliability of laboratory diagnostic tests. Smart technology-driven approaches to quality control are gaining popularity, enabling continuous monitoring and swift error detection and resolution. With the increasing demand for rapid and accurate diagnostic tests, smart quality control measures are essential in ensuring clinicians can rely on accurate and reliable diagnostic performance. As technology continues to evolve, it is expected that in-vitro diagnostic smart quality control measures will continue to improve, ensuring that healthcare providers can deliver safe and effective care.
- How big is the In-Vitro Diagnostics Quality Control Market?
- What is the In-Vitro Diagnostics Quality Control Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?